Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous drug delivery
Fierce Pharma
Halozyme CEO targets new deals as IRA uncertainty subsides
As drug developers gain a better grasp of the IRA’s impact, Halozyme has seen a ramp-up in deal discussions over its subcutaneous platform.
Angus Liu
Oct 14, 2025 9:40am
Fierce Pharma
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Lundbeck ends subcutaneous migraine cohort after futility review
Apr 1, 2025 5:00am
Glenmark bags subcutaneous checkpoint inhibitor rights
Jan 25, 2024 9:30am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm
ASH: Roche records rare disease win ahead of Soliris showdown
Dec 12, 2022 8:15am
